Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 114Lung Neoplasms 83Lymphoma 76Head and Neck Neoplasms 76Glioblastoma 75Squamous Cell Carcinoma of Head and Neck 71Breast Neoplasms 71Rectal Neoplasms 67Esophageal Neoplasms 63Prostatic Neoplasms 59Leukemia 57Central Nervous System Neoplasms 54Pancreatic Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Non-Hodgkin 43Lymphoma, Large B-Cell, Diffuse 43Hodgkin Disease 42Lymphoma, Follicular 41Brain Neoplasms 40Leukemia, Lymphocytic, Chronic, B-Cell 39Esophageal Squamous Cell Carcinoma 39Colorectal Neoplasms 38Burkitt Lymphoma 37Gliosarcoma 36Lymphoma, Large-Cell, Immunoblastic 33Uterine Cervical Neoplasms 31Neoplasms 31Adenocarcinoma Of Esophagus 31Lymphoma, Mantle-Cell 30Lymphoma, B-Cell, Marginal Zone 29

Interventions

Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hemoptysis × Radiotherapy × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡